肝硬化中西医结合治疗的研究进展

Research advances in integrated traditional Chinese and Western medicine therapy for liver cirrhosis

中西药并用是提高肝硬化治疗效果的重要途径,防治慢性乙型肝炎肝硬化长期诊疗实践及临床研究表明,针对病因的抗病毒联合抗肝纤维化中药治疗能够显著提高肝纤维化、肝硬化的逆转率,抗肝纤维化治疗可降低食管胃静脉曲张破裂出血率,减少肝硬化患者肝细胞癌的发生率,提高失代偿期肝硬化患者的5年生存率。深入研究中药复方的主要有效成分作用靶标及相关作用机制,加强药物质控标准的研究,以及获得更多高质量临床疗效证据是有效促进中西医结合治疗肝硬化领域发展亟待解决的主要问题。

The combination of traditional Chinese medicine and Western medicine is an important approach to improve the treatment outcome of liver cirrhosis. Long-term diagnosis and treatment practice and clinical studies of the prevention and treatment of chronic hepatitis B cirrhosis have shown that antiviral drugs targeting the cause of the disease combined with anti-liver fibrosis traditional Chinese medicine can significantly improve the reversal rate of liver fibrosis and cirrhosis, and anti-liver fibrosis therapy can reduce the incidence rates of esophagogastric variceal bleeding and hepatocellular carcinoma in cirrhotic patients and improve the 5-year survival rate of patients with decompensated liver cirrhosis. It is necessary to conduct in-depth studies to clarify the target and mechanism of action of the main effective constituents of compound traditional Chinese medicine, strengthen the research on drug quality control standards, and obtain more high-quality evidence for clinical efficacy, so as to effectively promote the development of integrated traditional Chinese and Western medicine therapy for liver cirrhosis.